Surgicel Reduces Ovarian Endometriomas Recurrence

Sponsor
Cairo University (Other)
Overall Status
Completed
CT.gov ID
NCT02947724
Collaborator
(none)
200
1
4
36
5.6

Study Details

Study Description

Brief Summary

Two hundred women aged from 20 to 35 years undergoing conservative laparoscopic treatment of ovarian endometriomas (either by drainage or cyst wall excision) were included. Participants were randomized into 4 groups; group A (drainage only) in which 50 patients underwent laparoscopic fenestration and electrocautery of the endometrioma cyst wall, group B (cystectomy only) in which 50 patients underwent laparoscopic excision of the endometrioma cyst wall, group C (drainage & Surgicel) in which 50 patients underwent laparoscopic fenestration of the endometrioma cyst wall followed by insertion of 4 pieces of Surgicel inside the cyst cavity, group D (cystectomy & Surgicel) in which 50 patients underwent laparoscopic excision of the endometrioma cyst wall followed by insertion of 4 pieces of Surgicel inside the remaining ovarian tissues.All patients were followed up every 3 months for 2 years following the laparoscopic surgery. The primary outcome was the recurrence of endometriomas in the ipsilateral ovary (recurrence was defined as the presence of ovarian cysts with the characteristic sonographic features of endometriomas (≥1 cm). The ovarian reserve was reassessed (AMH & day 2 AFC) as a secondary outcome 6 months following the laparoscopy.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

Two hundred women aged from 20 to 35 years undergoing conservative laparoscopic treatment of ovarian endometriomas (either by drainage or cyst wall excision) were included. Participants were randomized into 4 groups; group A (drainage only) in which 50 patients underwent laparoscopic fenestration and electrocautery of the endometrioma cyst wall, group B (cystectomy only) in which 50 patients underwent laparoscopic excision of the endometrioma cyst wall, group C (drainage & Surgicel) in which 50 patients underwent laparoscopic fenestration of the endometrioma cyst wall followed by insertion of 4 pieces of Surgicel inside the cyst cavity, group D (cystectomy & Surgicel) in which 50 patients underwent laparoscopic excision of the endometrioma cyst wall followed by insertion of 4 pieces of Surgicel inside the remaining ovarian tissues. Randomization was done using computer generated random numbers.

Inclusion criteria included endometriosis-related clinical manifestations (infertility, pelvic pain or pelvic mass), unilateral & unilocular endometrioma (≥5 cm), rapidly growing endometrioma & good ovarian reserve (antimullerian hormone > 1 ng/ml & antral follicular count > 4). Recurrent & bilateral cases were excluded. In addition, patients who were unfit for surgery, suffered chronic diseases (e.g. cardiac disease or diabetes) or had any contraindication for laparoscopic surgery (excessive anterior abdominal wall scarring) were also excluded.

For all patients, full history was taken followed by complete physical examination & laboratory investigations (AMH & routine preoperative investigations). Day 2 transvaginal ultrasound (TVUS) was done using a 7.5 MHz vaginal probe of the General Electric Voluson E8 ultrasound unit (GE Healthcare Austria GmbH, Seoul, Korea) to confirm the presence and assess the size and side of the endometrioma (ovarian cyst with homogeneous low-level ground glass echogenicity of the cystic fluid) & to assess the AFC (Number of visible follicles from 2 to 10 mm) in both the affected and healthy ovary.

Cystectomy or drainage was done by one of the investigators. In cystectomy groups (B&D), a small window (2cm) was done in the cyst wall using diathermy followed by aspiration of the chocolate material from the cyst then stripping the cyst wall from ovarian tissue using 2 non-traumatic graspers (by traction-counter traction technique) and finally irrigating the remaining ovarian tissues with normal saline. In drainage groups (A & C), a small window (2cm) was done in the cyst wall using diathermy followed by aspiration of the chocolate material from the cyst & then irrigation of the cyst cavity with normal saline. In non-Surgicel groups (A&B), haemostasis & destruction of the remaining endometriotic cyst wall was done by bipolar electrocautery. In Surgicel groups (C&D), each SURGICEL® (oxidized regenerated cellulose - Ethicon US, LLC.) knitted fabric (5 x 10 cm) was divided into four equal pieces inserted inside the cavity of the cyst (group C) or the remaining ovarian tissues (group D). If the ovarian edges were gaped, approximation was done using 1-3 interrupted sutures of 4/0 polydioxanone (PDS® Suture - Ethicon US, LLC.). All patients were followed up every 3 months for 2 years following the laparoscopic surgery. The primary outcome was the recurrence of endometriomas in the ipsilateral ovary (recurrence was defined as the presence of ovarian cysts with the characteristic sonographic features of endometriomas (≥1 cm). The ovarian reserve was reassessed (AMH & day 2 AFC) as a secondary outcome 6 months following the laparoscopy.

Study Design

Study Type:
Interventional
Actual Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Prevention
Official Title:
The Use of Surgicel in Preventing Recurrence of Ovarian Endometriomas During Laparoscopic Surgery
Actual Study Start Date :
Jan 1, 2016
Actual Primary Completion Date :
Jan 1, 2019
Actual Study Completion Date :
Jan 1, 2019

Arms and Interventions

Arm Intervention/Treatment
No Intervention: drainage only

50 patients underwent laparoscopic fenestration and electrocautery of the endometrioma cyst wall

No Intervention: cystectomy only

50 patients underwent laparoscopic excision of the endometrioma cyst wall

Active Comparator: drainage & Surgicel

50 patients underwent laparoscopic fenestration of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the cyst cavity

Drug: SURGICEL®
Insertion of 4 pieces of SURGICEL® inside the cyst cavity. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.

Active Comparator: cystectomy & Surgicel

50 patients underwent laparoscopic excision of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.

Drug: SURGICEL®
Insertion of 4 pieces of SURGICEL® inside the cyst cavity. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.

Outcome Measures

Primary Outcome Measures

  1. recurrence of endometriomas in the ipsilateral ovary [2 YEARS]

    recurrence was defined as the presence of ovarian cysts with the characteristic sonographic features of endometriomas (≥1 cm)

Secondary Outcome Measures

  1. biochemical ovarian reserve [6 months after laparoscopy]

    serum antimullerian hormone measuremnt

  2. ultrasonographic ovarian reserve [6 months following the operation]

    antral follicle count on day 2 using transvaginal ultrasound

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 35 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Endometriosis-related clinical manifestations (infertility, pelvic pain or pelvic mass)

  • Unilateral & unilocular endometrioma (≥5 cm),

  • Rapidly growing endometrioma

  • Good ovarian reserve (antimullerian hormone > 1 ng/ml & antral follicular count > 4).

Exclusion Criteria:
  • Recurrent & bilateral cases

  • Patients who were unfit for surgery, suffered chronic diseases (e.g. cardiac disease or diabetes)

  • PATIENTS had any contraindication for laparoscopic surgery (excessive anterior abdominal wall scarring) .

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kasr Elainy Hospital (Cairo University) Cairo Egypt 115431

Sponsors and Collaborators

  • Cairo University

Investigators

  • Principal Investigator: moutaz elsherbini, MD, Assistant professor of obstetrics and gynecology - Cairo university

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Moutaz Sherbini, Assistant professor, Cairo University
ClinicalTrials.gov Identifier:
NCT02947724
Other Study ID Numbers:
  • 111949
First Posted:
Oct 28, 2016
Last Update Posted:
Apr 16, 2019
Last Verified:
Apr 1, 2019
Keywords provided by Moutaz Sherbini, Assistant professor, Cairo University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 16, 2019